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Mean muscle attenuation correlates with severe
acute pancreatitis unlike visceral adipose tissue
and subcutaneous adipose tissue
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Abstract
Background: Acute pancreatitis (AP) is a frequent disorder with considerable morbidity and mortality. Obesity has previously
been reported to influence disease severity.
Objective: The aim of this study was to investigate the association of adipose and muscle parameters with the severity
grade of AP.
Methods: In total 454 patients were recruited. The first contrast-enhanced computed tomography of each patient was
reviewed for adipose and muscle tissue parameters at L3 level. Associations with disease severity were analysed through
logistic regression analysis. The predictive capacity of the parameters was investigated using receiver operating character-
istic (ROC) curves.
Results: No distinct variation was found between the AP severity groups in either adipose tissue parameters (visceral
adipose tissue and subcutaneous adipose tissue) or visceral muscle ratio. However, muscle mass and mean muscle attenu-
ation differed significantly with p-values of 0.037 and 0.003 respectively. In multivariate analysis, low muscle attenuation
was associated with severe AP with an odds ratio of 4.09 (95% confidence intervals: 1.61–10.36, p-value 0.003). No body
parameter presented sufficient predictive capability in ROC-curve analysis.
Conclusions: Our results demonstrate that a low muscle attenuation level is associated with an increased risk of severe AP.
Future prospective studies will help identify the underlying mechanisms and characterise the influence of body composition
parameters on AP.
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Key summary
Established knowledge
. Acute pancreatitis is one of the most frequent gastrointestinal disorders implicating patient suﬀering and
economical burden on healthcare systems;
. Studies on the association between obesity and severity of acute pancreatitis have yielded heterogeneous
results.
New findings
. In this large European cohort, muscle mass and muscle attenuation are important parameters for the
outcome of acute pancreatitis;
. No association between visceral fat parameters and severity of acute pancreatitis was found in multivari-
ate analysis;
. None of the body parameters are useful as predictive markers for severe disease.
Introduction
Acute pancreatitis (AP) is one of the most frequent
diagnoses among gastrointestinal disorders requiring
hospitalisation.1 The course of the disease varies sub-
stantially, from self-restricting without complications
to multi-organ failure and considerable risk of death.
Multiple prognostic scoring systems, both clinical and
radiological, have been developed, however none with
suﬃcient predictive capacity.2 Furthermore, the key
steps of the pathophysiological mechanisms underlying
AP are to a large extent unknown.
Multiple reports have demonstrated an association
between obesity and worse outcome of AP.3–5 Body
mass index (BMI) has been used as a surrogate for
obesity, with high BMI considered an independent
and established risk factor for severe AP.6,7 BMI has
also been proposed as a prognostic variable to be
included in scoring systems.8 However, in more recent
studies the impact of BMI has not been conﬁrmed.9
Rather, it seems to be the individual distribution of
corporal fat that inﬂuences the outcome in AP.10–12
The pancreas is surrounded by visceral adipose tissue
(VAT). As pro-inﬂammatory cytokines are secreted by
VAT during AP, VAT has been suggested to be a major
factor in the devolvement of peripancreatic necrosis.13
Release of unsaturated fatty acids induce necrosis, sys-
temic inﬂammation and organ failure.14 The secretion is
signiﬁcantly greater in the VAT than in the subcutane-
ous adipose tissue (SAT).15 Nevertheless, there are
several reports where no association between VAT,
SAT and severity of AP was found.5,16–18
It is well known that sarcopenia, regardless of
patient BMI, has been associated with poor prognosis
and increased risk of complications and morbidity in
cancer patients.19 The inﬂuence of muscle parameters
such as muscle mass (MM), mean muscle attenuation
(MMA) and visceral muscle ratio (VMR) on disease
outcome has not been thoroughly analysed in AP
with only a few papers published.16,17
In summary the results of previous works are het-
erogeneous and for certain parameters the number of
studies is insuﬃcient for making general conclusions.
Through this large European multicentre study we
aimed to assess the signiﬁcance of adipose and muscle
parameters in the severity development of AP.
Materials and methods
Patients
Patients for this study were identiﬁed through a post
hoc analysis of an established European multicentre
cohort (involving six centres: Lund, Sweden; Helsinki,
Finland; Barcelona, Spain; Tallinn, Estonia; Kaunas,
Lithuania and Soﬁa, Bulgaria) as well as additional
patients from two German centres (Halle and
Leipzig).20 In all centres, patients older than 18 years
with a ﬁrst episode of AP were retrospectively and con-
secutively enrolled. In the original six European centres
patients were identiﬁed from January 2012 to January
2013, and in the two German centres the inclusion
period was from January 2010 to January 2016. AP
was deﬁned by fulﬁlment of at least two out of three
criteria: acute upper abdominal pain, serum amylase
3 times the upper limit, or characteristic ﬁndings on
computed tomography (CT). At each centre in the
European cohort 50 AP patients in whom at least one
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contrast-enhanced CT (CECT) was performed were
included. In the German centres all available AP
patients with at least one CECT within the investigated
time frame were recruited. Severity of AP was assessed
according to the revised Atlanta criteria.21 Patients
were classiﬁed as mild (no complications), moderately
severe (organ failure for less than 48 h, deﬁned morpho-
logical ﬁndings on CT or deterioration of a previous
comorbidity) and severe AP (organ failure for more
than 48 h).
Patients with known chronic pancreatitis, signs
of chronic pancreatitis on CECT or with a CECT of
insuﬃcient quality were excluded. Ethical approval was
obtained at the Martin Luther University of Halle-
Wittenberg (date 21 July 2018, Bearbeitungsnummer
2017-96, Ethik-Kommission Medizinsche Fakulta¨t,
Martin Luther Universita¨t Halle-Wittenberg). Due to
the retrospective nature of the study and anonymisa-
tion of all data no informed consent was requested. The
study protocol conforms to the ethical guidelines of the
1975 Declaration of Helsinki (6th revision, 2008).
Body composition parameters
The ﬁrst CECT performed after onset of AP was
retrieved for all patients. Adipose tissue and muscle par-
ameters were measured using DCMtool and OsiriXLite
v9.0 (Pixmeo SARL, Geneva, Switzerland) for which
excellent inter-observer agreement has previously been
found.22 A cross-sectional slice at the level of the L3
vertebra body was selected, and regions of interest
(ROI) including the compartments of muscles and adi-
pose tissue were drawn manually (see Figure 1). Visible
peripancreatic necrosis and stranding extending to this
area were present only in rare cases and thus not
excluded from the measurements. Within the ROIs
tissue was selected by the speciﬁc ranges 190 to 30
Hounsﬁeld units (HU) for adipose tissue and30 to 150
for muscle tissue, as reported earlier.23 For visualisation
of the separate ROIs see Supplementary Figure 1, A–E.
VMR equals MM/VAT. The mean muscle attenuation
(MMA) was extracted from the histogram in the range
of 29 to þ150 HU (see illustrative histogram in
Supplementary Figure 1, A–E). As the measurement of
myosteatosis is inﬂuenced by the CT phase, solely CTs
performed in the native or venous phases were used for
this analysis.24 All analyses were performed by two inde-
pendent investigators (MJM and LEK) together with a
radiologist specialised in gastroenterological radiology
(NL). To test the inter-observer variability of the ana-
lyses, a randomised sub selection of 35 CECTs (7.7% of
the total cohort) was analysed a second time by MJM in
a blinded manner. Inter-observer agreement coeﬃcients
were between 0.873 and 1.0 for all parameters, with a
mean coeﬃcient value of 0.954.
Statistical analysis
Data is presented as absolute numbers and percentages
for categorical variables, and as median and interquar-
tile range (IQR) for continuous variables. Categorical
variables were compared using the chi-square test and
Mann–Whitney U for continuous data. As normality
was not assumed, the Mann–Whitney U or the
Kruskal–Wallis tests were performed for comparison
between groups. Possible associations between mea-
sured parameters and severe AP were investigated
through univariate and multivariate logistic regression
Figure 1. Regions of interest (ROI) of the distinct body compartments were visualised and defined by DCMTool. In (a) compartments for
fat measurements are shown. The subcutaneous compartment is located between the blue lines. The visceral compartment resides within
the green line. In (b) muscle compartments are demonstrated. Abdominal muscles are highlighted in blue, the Psoas muscle in red, and
the muscles of the back in green. For more details of the measurements see Supplementary Figure 1 A-E.
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analysis. In multivariate analysis the data was adjusted
for gender and age, where the latter was dichotomised at
the upper IQR level (73 years). In addition, in both uni-
variate and multivariate analysis the body composition
parameters were separated into three groups (tertiles)
based on the lowest, middle and highest IQR level of
each parameter. Results of the regression analysis are
presented as odds ratios (ORs) and adjusted odds
ratios (aORs) with corresponding 95% conﬁdence inter-
vals (CIs) and p-values. To test the predictive capacity of
the measured parameters receiver operating characteris-
tic (ROC) curves with corresponding areas under the
curves were performed. In all analysis a p-value of
0.05 was considered statistically signiﬁcant.
All calculations were performed using the SPSS
statistics software version 24 (IBM Corp., Armonk,
NY, USA).
Results
Patients
In total, 454 patients (58.1% males) were enrolled.
Baseline characteristic data of all patients is sum-
marised in Table 1. A majority of the patients
(49.6%) had a moderately severe disease course.
There were no signiﬁcant diﬀerences in age or BMI
between the severity grades. Biliary-caused pancreatitis
was the most common aetiology (41.6%). Transient or
persistent organ failure developed in 25.1% of the
patients and overall mortality was 6.6% (30 patients).
Muscle and adipose parameters
Among the 454 CTs analysed, 183 were performed in
the native-, 243 in the venous- and 28 in the arterial
phase. No signiﬁcant diﬀerence was found between the
phases either for the two adipose tissue parameters
(VAT and SAT) or two of the three muscle tissue par-
ameters (MM and VMR). As described in the Methods
section, the analysis of MMA solely included native
and venous CTs. Median time from admission to CT
was 3 days (IQR 1–7) with no signiﬁcant diﬀerence
between severity groups.
Table 2 presents median values and IQRs of the mea-
sured variables. For VAT, SAT and VMR no distinct
variation was found between the groups with mild, mod-
erately severe or severe AP. For MM and MMA the
diﬀerences were signiﬁcant with p-values of 0.037 and
0.003 respectively. Gender-speciﬁc median values for
men were VAT: 252.6 (IQR 173.0–335.3) cm2, SAT:
181.5 (IQR 132.7–235.9) cm2, MM: 152.2 (IQR 132.0–
170.3) cm2, MMA: 32.2 (IQR 24.4–38.6) HU and VMR:
1.64 (IQR 1.20–2.18) cm2. Corresponding values for
women were VAT: 171.1 (IQR 111.7–232.5) cm2, SAT:
260.1 (IQR 183.1–345.2) cm2, MM: 104.6 (IQR 92.7–
116.7) cm2, MMA 25.4 (IQR 19.5–32.9) HU and
VMR: 1.65 (IQR 1.05–2.18) cm2. The gender variations
diﬀered signiﬁcantly (p< 0.0001) for all parameters but
for VMR where no disparity was found.
Additional analysis was performed for the temporal
impact of AP on the corporal parameters. For 41 con-
secutive CTs (ﬁrst CT versus second CT) body
Table 1. Patient characteristics.
Total Mild Moderately severe Severe
N¼ 454 N¼ 163 (35.9%) N¼ 225 (49.6%) N¼ 66 (14.5%)
Gender (%)
Male 264 (58.1) 92 (34.8) 132 (50.0) 40 (15.2)
Female 190 (41.9) 71 (37.4) 93 (48.9) 26 (13.7)
Age (years)* 60 (46–73) 63.0 (49–74) 56 (43–68) 63 (48–77)
BMI (kg/m2)* 27.7 (24.8–31.1) 27.7 (24.8–31.0) 27.8 (24.8–31.1) 27.5 (24.3–30.8)
Aetiology (%#)
Biliary 189 (41.6) 74 (45.4) 96 (42.7) 19 (28.1)
Alcohol 135 (29.7) 40 (24.5) 73 (32.4) 22 (33.3)
Idiopathic 93 (20.5) 36 (22.1) 44 (19.6) 13 (19.7)
Others 37 (8.1) 13 (7.0) 12 (5.3) 12 (18.2)
Organ failure (%) 114 (25.1) 0 48 (42.1) 66 (100)
Mortality (%) 30 (6.6) 1 (0.6) 4 (1.8) 25 (37.9)
Timing of CT (days)* 3 (1–7) 3 (1–5) 4 (1–9) 3 (1–7)
Note: *Values are in median (IQR).
#Distribution of aetiologies among severity groups.
BMI¼ body mass index (kg/m2).
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parameter measurements were compared. Signiﬁcant
diﬀerences were found in the moderately severe group
for VAT (VATearlymean¼ 240.1 cm2 vs. VATlatemean¼
220.5 cm2; p-value 0.0083) and MM (MMearlymean¼
131.2 cm2 vs. MMlatemean¼ 123.8 cm2; p-value
0.0003); see Supplementary Table 1.
Regression analysis
The results from the univariate and multivariate (age
and gender adjusted) regression analyses are sum-
marised in Table 3. Age, gender and BMI were in nei-
ther analysis associated with severe AP. For VAT and
SAT, the lowest tertile was set as reference for the ORs
(OR¼ 1). This approach was chosen as we assumed it
was favourable to have less VAT and SAT with regard
to the development of severe AP. We likewise expected
a higher proportion of muscles to be beneﬁcial for the
course of the disease. Thus for the muscle parameters
MM, MMA and VMR, the highest tertile is reference
(OR¼ 1). The majority of parameters did not signiﬁ-
cantly correlate with severe disease. However, signiﬁ-
cant association with severe AP was found in univariate
analysis for the patients with the highest tertile of VAT
(OR 2.24, p-value 0.042) and the lowest tertile of MMA
(OR 3.446, p-value 0.0004). In multivariate analysis the
correlation remained for the MMA tertile (OR 4.09,
p-value 0.003). In addition, the patients in the MM
mid-tertile group demonstrated a distinctly lower risk
(OR 0.496, p-value 0.038) of developing severe AP.
Further adjustment of multivariate regression analysis
regarding aetiology and time of CT (days) yielded only
marginal changes (see Supplementary Table 2).
ROC curves
For each parameter a ROC curve was performed (see
Supplementary Figure 2, A–E) to analyse their predict-
ive capacity. In summary, all areas under the curves
were small (range 0.424–0.571) and no cut-oﬀ value
for severe AP could be retrieved.
Discussion
As obesity increasingly aﬀects healthcare systems world-
wide we aimed to investigate possible associations
between severe AP and body composition parameters.
Our results indicate that MM and muscle attenuation
are important parameters for the outcome of AP. We
were not able to demonstrate any association between
either BMI level or corporal fat parameters and severe
AP.Moreover, none of the investigated markers showed
any prognostic capability in ROC-curve analysis.
Former studies have, using BMI as a surrogate
marker, presented evidence that obesity has a negative
impact on the disease course in AP.3–7 More recent
works have investigated other parameters such as
VAT and SAT.10–12 However, results have been contra-
dictory and a correlation between these markers with
AP severity is still unclear.5,18–20,25 Regarding BMI, our
Table 2. Association between body composition parameters and severity of acute pancreatitis.
All Mild
Moderately
severe Severe p-value
VAT
Median 217.3 221.2 208.1 238.8 0.10a
IQR 139.7–290.5 144.9–283.6 131.7–287.5 172.1–333.5
SAT
Median 209.2 204.5 213.5 212.0 0.97a
IQR 145.0– 285.1 151.9 – 274.8 141.6 – 289.6 144.8 – 281.6
MM
Median 129.5 126.6 130.0 136.9 0.037a
IQR 105.3–158.6 100.1–153.4 108.0–160.1 108.1–169.4
MMA
Median 29.3 29.8 29.6 23.4 0.003a
IQR 22.2–36.6 22.4–37.8 23.2–37.1 18.3–32.1
VMR
Median 1.64 1.76 1.57 1.73 0.14a
IQR 1.14–2.18 1.14–2.23 1.04–2.11 1.27–2.38
Note: VAT¼ visceral adipose tissue; SAT¼ subcutaneous adipose tissue; MM¼muscle mass; MMA¼mean muscle attenuation;
VMR¼ visceral muscle ratio; VAT, SAT, MM and VMR in cm2, MMA in HU.
aKruskal–Wallis test.
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data was in line with that of several other studies,
demonstrating that BMI in itself does not inﬂuence
the grade of severity in AP.3,9,26 In our cohort the
very small subgroup (n¼ 3) of underweight patients
(BMI<18 kg/m2) demonstrated a signiﬁcant associ-
ation with decreased risk of severe AP (OR 0.001,
95% CI 0–0.002, p-value 0.001). These results, however,
lack reliability due to the small sample size. The inﬂu-
ence of a very low BMI on the outcome of AP patients
needs further investigation.
The impact and relevance of intra-corporal adipose
tissue distribution on AP severity has been debated.3
When reviewing previous investigations of VAT and
SAT, considerable diﬀerences were found compared
with our data. Herein, the median value of VAT was
217.3 cm2 and 209.2 cm2 for SAT. Several studies that
demonstrated a correlation between adipose tissue par-
ameters and severe AP also reported lower levels of
VAT and SAT in the groups with mild (median levels
80–105 cm2) and moderately severe AP (median levels
89–150 cm2).10–12 This evident variation compared with
our data is interesting, though diﬃcult to explain.
Referred works investigated diﬀerent populations (one
American and two Asian) with diverse aetiologies, used
Table 3. Univariate and multivariate regression analysis of risk factors for severe acute pancreatitis. Age was dichotomised at 73 years
(highest tertile in the IQR).
Logistic regression analysis of risk factors for severe AP
Univariate
OR (95% CI) p-value
Multivariate
aOR (95% CI) p-value
Gender
Female 1 (ref)
Male 1.126 (0.661–1.920) 0.662 1.217 (0.682–2.172) 0.505
Age
<73 years 1 (ref)
73 years 1.609 (0.916–2.824) 0.098 1.495 (0.815–2.745) 0.194
BMI
>25.0 1 (ref)
18.5–24.9 0.998 (0.517–1.863) 0.528 0.981 (0.517–1.863) 0.954
<18.5 0.001 (0.000–0.002) 0.001 0.001 (0.000–0.002) 0.001
VAT
Highest tertile 2.242 (1.031–4.876) 0.042 2.157 (0,953–4.883) 0.065
Mid tertile 1.569 (0.761–3.234) 0.222 1.551 (0.750–3.207) 0.236
Lowest tertile 1 (ref)
SAT
Highest tertile 0.923 (0.420–2.027) 0.841 0.921 (0.395–2.148) 0.848
Mid tertile 0.994 (.508–1.946) 0.987 0.982 (0.499–1.932) 0.958
Lowest tertile 1 (ref)
MM
Highest tertile 1 (ref)
Mid tertile 0.596 (0.324–1.094) 0.095 0.496 (0.256–0.961) 0.038
Lowest tertile 0.625 (0.306–1.094) 0.199 0.432 (0.166– 1.124) 0.085
MMA
Highest tertile 1 (ref)
Mid tertile 1.536 (0.670–3.519) 0.311 1.577 (0.683–3.640) 0.286
Lowest tertile 3.446 (1.468–8.086) 0.0004 4.085 (1.609–10.37) 0.003
VMR
Highest tertile 1 (ref)
Mid tertile 0.921 (0.494–1.714) 0.794 1.025 (0.538–1.954) 0.940
Lowest tertile 0.587 (0.268–1.287) 0.184 0.673 (0.300–1.508) 0.336
Note: OR¼ odds ratio; VAT¼ visceral adipose tissue; SAT¼ subcutaneous adipose tissue; MM¼muscle mass; MMA¼mean muscle attenuation;
VMR¼ visceral muscle ratio.
Multivariate analysis: results adjusted for age and gender.
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various software programs in analyses and, ﬁnally, not
all followed the same classiﬁcation of AP. Our results
were consistent throughout the European countries and
also comparable with a recent publication from the
Netherlands investigating the association between CT-
assessed body composition with mortality in patients
with necrotising pancreatitis, as well as an Australian
study on intensive care patients.16,17 As our method-
ology is similar to the one in the Dutch study and the
median values of VAT and SAT vary considerably
between the American and Asian studies, we speculate
that the observed variations are based on geographical
or ethnical diﬀerences. Regarding adipose tissue par-
ameters, several works report similar conclusions to
ours5,16–18; however, these studies diﬀer in both inves-
tigated outcomes and set-up, making direct comparison
with our ﬁndings diﬃcult.
As we observed a correlation of VAT with severity in
univariate- (OR 2.24; 95% CI 1.03–4.88; p-value 0.04)
but not in multivariate analysis (p-value 0.07) we won-
dered whether AP itself might inﬂuence VAT measure-
ment. The results presented in Supplementary Table 1
and Supplementary Figure 3 demonstrate a signiﬁcant
diﬀerence in VAT and MM for the moderately severe
group. The decrease in VAT over time in both the mod-
erately severe and severe groups might mirror a general
disease-induced reduction in adipose tissue as there is a
similar tendency in the SAT group. A direct compari-
son of the ﬁrst and second CTs revealed that the meas-
urement of VAT was inﬂuenced by parameters like
bowel distension, the volume of the thoracic cavity
and by ﬂuid collections due to AP. Furthermore, the
MM demonstrated a general decline, which might be
due to patients being ill and hospitalised and thus in a
state of muscle reduction and general oedema. The pre-
viously mentioned work from the Netherlands found a
correlation with MM depletion during the disease
course, which we were able to partially replicate in
our consecutive CTs.16 Nonetheless, it is diﬃcult to
make general conclusions in such cases based on retro-
spective data, and prospective trials with predeﬁned
protocols are needed.
The inﬂuence of muscle parameter levels has not
been extensively investigated in AP. Our analyses
depicted a higher MM in severe AP (136.9 cm2)
compared with moderately severe (130 cm2) or mild
(126.6 cm2) cases (p-value 0.037). These numbers sur-
prised us as low MM generally correlated with worse
outcome in diseases. A hypothesis is that the severely ill
patients already at a very early stage of the disease
demonstrated more ﬂuid sequestration and that
oedema consequently inﬂuenced the measuring, giving
falsely high values. Similarly, in multivariate analysis,
lower levels of MM were unexpectedly associated with
less severe AP, however, this was signiﬁcant for the
mid-tertile only (p-value 0.038). The lowest tertile for
MM presented a p-value of 0.085, which might be due
to a lower number of patients creating a type 2 error in
this subgroup. The highest tertile of MM was set as
reference as we assumed this to be favourable with
regard to severity outcome. With our results demon-
strating the opposite, despite being adjusted for age
and gender, we again think oedema might be an inﬂu-
encing factor. This theory can neither be conﬁrmed in
this study, nor have we found any other to compare it
with. In the work by Brewster et al., only patients with
severe AP were investigated and their level of MM was
167.8 (144.2–203.7) cm2, which is in line with our ﬁg-
ures.17 However, patients in the Australian study were
younger and no data was provided regarding on what
day during the course of the disease the investigated CT
was performed.
In our work, a low level of MMA, indicating
myosteatosis, demonstrated a strong association
with severity (aOR 4.1, 95% CI 1.6–10.4, p-value
0.003). In addition, its measurement was not inﬂu-
enced by the disease course (Supplementary Table 1;
p-value 0.215). This observation is, again, partly sup-
ported by the study from van Grinsven et al. who
analysed the correlation of MMA with mortality in
AP patients and found a distinct association in the
univariate analysis (OR 2.37, 95% CI 1.43–3.92, p-
value 0.001) that, however, was not signiﬁcant in the
multivariate analysis (OR 1.13, 95% CI 0.62–2.08, p-
value 0.69).16 MMA characterises the intramuscular,
and not the intermuscular, fat content. Low muscle
attenuation has previously been related to poor prog-
nosis and increased risk of complications and mor-
bidity in cancer patients.19 It has been proposed
that fat inﬁltration underlies reduced muscle attenu-
ation, whereas the composition of the intramuscular
accumulated fat is largely unknown. Although myos-
teatosis has been associated with diﬀerent patho-
logical conditions, the underlying mechanisms are
poorly elucidated making it impossible to explain its
impact on severity in AP.
Our study has several limitations. The retrospective
nature of the study implicated that there was no exact
predeﬁned study protocol for the CECTs, although all
centres used equal standard protocols when investi-
gating the pancreas. Moreover, only patients who
had a CECT performed were included, potentially
introducing selection bias, as patients with a mild dis-
ease course but no CECT performed were not
enrolled. According to AP guidelines, patients with
mild disease do not require a CECT unless another
diagnosis needs to be excluded.27 As a result, the
group of patients with mild AP is likely to be smaller
in radiology studies, as well as those with moderately
severe diseases are more numerous compared with
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studies with consecutive inclusion of all AP patients.28
We also acknowledge that the impact of oedema on
our results, as well as those of all previous studies on
body parameters in AP, remains largely unknown.
However, herein we collated a large, well-charac-
terised AP cohort from centres all over Europe,
aﬀording our study a robust research methodology.
The pan-European multicentre setting additionally
provides less risk of disproportion regarding basal
patient characteristics and cultural variations.
In conclusion, our results cannot conﬁrm prior ﬁnd-
ings that obesity per se or distinct visceral fat param-
eters are associated with severity in AP. The data
presented indicates that patients with low MM have a
better outcome, while a low MMA correlates with
severe disease. Both observations are however in need
of further investigation to understand the underlying
mechanisms. As our results, as well as those from pre-
vious studies, to a large extent stem from retrospective
analyses, a similar but prospective study including
patients from diﬀerent geographical regions would
seem pertinent to address the questions that remain
unanswered. Lastly, it is our opinion that understand-
ing the function and inﬂuence of adipose tissue within
the abdominal cavity is one of several key requirements
for a profound knowledge of the pathophysiological
processes in severe AP.
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